Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells

M. Danielle Bareford, Margaret A. Park, Adly Yacoub, Hossein A. Hamed, Yong Tang, Nichola Cruickshanks, Patrick Eulitt, Nisan Hubbard, Gary Tye, Matthew E. Burow, Paul B. Fisher, Richard G. Moran, Kenneth Nephew, Steven Grant, Paul Dent

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Pemetrexed (ALIMTA, Lilly) is a folate antimetabolite that has been approved by the U.S. Food and Drug Administration for the treatment of non-small cell lung cancer and has been shown to stimulate autophagy. In the present study, we sought to further understand the role of autophagy in response to pemetrexed and to test if combination therapy could enhance the level of toxicity through altered autophagy in tumor cells. The multikinase inhibitor sorafenib (Nexavar, Bayer), used in the treatment of renal and hepatocellular carcinoma, suppresses tumor angiogenesis and promotes autophagy in tumor cells. We found that sorafenib interacted in a greater than additive fashion with pemetrexed to increase autophagy and to kill a diverse array of tumor cell types. Tumor cell types that displayed high levels of cell killing after combination treatment showed elevated levels of AKT, p70 S6K, and/or phosphorylated mTOR, in addition to class III receptor tyrosine kinases such as platelet-derived growth factor receptor beta and VEGF receptors, known in vivo targets of sorafenib. In xenograft and in syngeneic animal models of mammary carcinoma and glioblastoma, the combination of sorafenib and pemetrexed suppressed tumor growth without deleterious effects on normal tissues or animal body mass. Taken together, the data suggest that premexetred and sorafenib act synergistically to enhance tumor killing via the promotion of a toxic form of autophagy that leads to activation of the intrinsic apoptosis pathway, and predict that combination treatment represents a future therapeutic option in the treatment of solid tumors.

Original languageEnglish
Pages (from-to)4955-4967
Number of pages13
JournalCancer Research
Volume71
Issue number14
DOIs
StatePublished - Jul 15 2011

Fingerprint

Pemetrexed
Autophagy
Neoplasms
Animal Mammary Neoplasms
Platelet-Derived Growth Factor beta Receptor
Antimetabolites
Vascular Endothelial Growth Factor Receptor
sorafenib
Poisons
Receptor Protein-Tyrosine Kinases
United States Food and Drug Administration
Glioblastoma
Folic Acid
Heterografts
Non-Small Cell Lung Carcinoma
Hepatocellular Carcinoma
Animal Models

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bareford, M. D., Park, M. A., Yacoub, A., Hamed, H. A., Tang, Y., Cruickshanks, N., ... Dent, P. (2011). Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Research, 71(14), 4955-4967. https://doi.org/10.1158/0008-5472.CAN-11-0898

Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. / Bareford, M. Danielle; Park, Margaret A.; Yacoub, Adly; Hamed, Hossein A.; Tang, Yong; Cruickshanks, Nichola; Eulitt, Patrick; Hubbard, Nisan; Tye, Gary; Burow, Matthew E.; Fisher, Paul B.; Moran, Richard G.; Nephew, Kenneth; Grant, Steven; Dent, Paul.

In: Cancer Research, Vol. 71, No. 14, 15.07.2011, p. 4955-4967.

Research output: Contribution to journalArticle

Bareford, MD, Park, MA, Yacoub, A, Hamed, HA, Tang, Y, Cruickshanks, N, Eulitt, P, Hubbard, N, Tye, G, Burow, ME, Fisher, PB, Moran, RG, Nephew, K, Grant, S & Dent, P 2011, 'Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells', Cancer Research, vol. 71, no. 14, pp. 4955-4967. https://doi.org/10.1158/0008-5472.CAN-11-0898
Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N et al. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Research. 2011 Jul 15;71(14):4955-4967. https://doi.org/10.1158/0008-5472.CAN-11-0898
Bareford, M. Danielle ; Park, Margaret A. ; Yacoub, Adly ; Hamed, Hossein A. ; Tang, Yong ; Cruickshanks, Nichola ; Eulitt, Patrick ; Hubbard, Nisan ; Tye, Gary ; Burow, Matthew E. ; Fisher, Paul B. ; Moran, Richard G. ; Nephew, Kenneth ; Grant, Steven ; Dent, Paul. / Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. In: Cancer Research. 2011 ; Vol. 71, No. 14. pp. 4955-4967.
@article{fc4ded65db9e40d682fa11b195f3f9a3,
title = "Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells",
abstract = "Pemetrexed (ALIMTA, Lilly) is a folate antimetabolite that has been approved by the U.S. Food and Drug Administration for the treatment of non-small cell lung cancer and has been shown to stimulate autophagy. In the present study, we sought to further understand the role of autophagy in response to pemetrexed and to test if combination therapy could enhance the level of toxicity through altered autophagy in tumor cells. The multikinase inhibitor sorafenib (Nexavar, Bayer), used in the treatment of renal and hepatocellular carcinoma, suppresses tumor angiogenesis and promotes autophagy in tumor cells. We found that sorafenib interacted in a greater than additive fashion with pemetrexed to increase autophagy and to kill a diverse array of tumor cell types. Tumor cell types that displayed high levels of cell killing after combination treatment showed elevated levels of AKT, p70 S6K, and/or phosphorylated mTOR, in addition to class III receptor tyrosine kinases such as platelet-derived growth factor receptor beta and VEGF receptors, known in vivo targets of sorafenib. In xenograft and in syngeneic animal models of mammary carcinoma and glioblastoma, the combination of sorafenib and pemetrexed suppressed tumor growth without deleterious effects on normal tissues or animal body mass. Taken together, the data suggest that premexetred and sorafenib act synergistically to enhance tumor killing via the promotion of a toxic form of autophagy that leads to activation of the intrinsic apoptosis pathway, and predict that combination treatment represents a future therapeutic option in the treatment of solid tumors.",
author = "Bareford, {M. Danielle} and Park, {Margaret A.} and Adly Yacoub and Hamed, {Hossein A.} and Yong Tang and Nichola Cruickshanks and Patrick Eulitt and Nisan Hubbard and Gary Tye and Burow, {Matthew E.} and Fisher, {Paul B.} and Moran, {Richard G.} and Kenneth Nephew and Steven Grant and Paul Dent",
year = "2011",
month = "7",
day = "15",
doi = "10.1158/0008-5472.CAN-11-0898",
language = "English",
volume = "71",
pages = "4955--4967",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells

AU - Bareford, M. Danielle

AU - Park, Margaret A.

AU - Yacoub, Adly

AU - Hamed, Hossein A.

AU - Tang, Yong

AU - Cruickshanks, Nichola

AU - Eulitt, Patrick

AU - Hubbard, Nisan

AU - Tye, Gary

AU - Burow, Matthew E.

AU - Fisher, Paul B.

AU - Moran, Richard G.

AU - Nephew, Kenneth

AU - Grant, Steven

AU - Dent, Paul

PY - 2011/7/15

Y1 - 2011/7/15

N2 - Pemetrexed (ALIMTA, Lilly) is a folate antimetabolite that has been approved by the U.S. Food and Drug Administration for the treatment of non-small cell lung cancer and has been shown to stimulate autophagy. In the present study, we sought to further understand the role of autophagy in response to pemetrexed and to test if combination therapy could enhance the level of toxicity through altered autophagy in tumor cells. The multikinase inhibitor sorafenib (Nexavar, Bayer), used in the treatment of renal and hepatocellular carcinoma, suppresses tumor angiogenesis and promotes autophagy in tumor cells. We found that sorafenib interacted in a greater than additive fashion with pemetrexed to increase autophagy and to kill a diverse array of tumor cell types. Tumor cell types that displayed high levels of cell killing after combination treatment showed elevated levels of AKT, p70 S6K, and/or phosphorylated mTOR, in addition to class III receptor tyrosine kinases such as platelet-derived growth factor receptor beta and VEGF receptors, known in vivo targets of sorafenib. In xenograft and in syngeneic animal models of mammary carcinoma and glioblastoma, the combination of sorafenib and pemetrexed suppressed tumor growth without deleterious effects on normal tissues or animal body mass. Taken together, the data suggest that premexetred and sorafenib act synergistically to enhance tumor killing via the promotion of a toxic form of autophagy that leads to activation of the intrinsic apoptosis pathway, and predict that combination treatment represents a future therapeutic option in the treatment of solid tumors.

AB - Pemetrexed (ALIMTA, Lilly) is a folate antimetabolite that has been approved by the U.S. Food and Drug Administration for the treatment of non-small cell lung cancer and has been shown to stimulate autophagy. In the present study, we sought to further understand the role of autophagy in response to pemetrexed and to test if combination therapy could enhance the level of toxicity through altered autophagy in tumor cells. The multikinase inhibitor sorafenib (Nexavar, Bayer), used in the treatment of renal and hepatocellular carcinoma, suppresses tumor angiogenesis and promotes autophagy in tumor cells. We found that sorafenib interacted in a greater than additive fashion with pemetrexed to increase autophagy and to kill a diverse array of tumor cell types. Tumor cell types that displayed high levels of cell killing after combination treatment showed elevated levels of AKT, p70 S6K, and/or phosphorylated mTOR, in addition to class III receptor tyrosine kinases such as platelet-derived growth factor receptor beta and VEGF receptors, known in vivo targets of sorafenib. In xenograft and in syngeneic animal models of mammary carcinoma and glioblastoma, the combination of sorafenib and pemetrexed suppressed tumor growth without deleterious effects on normal tissues or animal body mass. Taken together, the data suggest that premexetred and sorafenib act synergistically to enhance tumor killing via the promotion of a toxic form of autophagy that leads to activation of the intrinsic apoptosis pathway, and predict that combination treatment represents a future therapeutic option in the treatment of solid tumors.

UR - http://www.scopus.com/inward/record.url?scp=79960410571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960410571&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-11-0898

DO - 10.1158/0008-5472.CAN-11-0898

M3 - Article

C2 - 21622715

AN - SCOPUS:79960410571

VL - 71

SP - 4955

EP - 4967

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 14

ER -